Characterization_NN
of_IN
interleukin-10_NN
receptor_NN
expression_NN
on_IN
B-cell_NN
chronic_JJ
lymphocytic_JJ
leukemia_NN
cells_NNS
._.

B-cell_NN
chronic_JJ
lymphocytic_JJ
leukemia_NN
-LRB-_-LRB-
B-CLL_NN
-RRB-_-RRB-
cells_NNS
accumulate_VBP
in_FW
vivo_FW
in_IN
the_DT
G0\/G1_NN
phase_NN
of_IN
the_DT
cell_NN
cycle_NN
,_,
suggesting_VBG
that_IN
their_PRP$
malignant_JJ
expansion_NN
is_VBZ
due_JJ
,_,
at_IN
least_JJS
in_IN
part_NN
,_,
to_TO
a_DT
delay_NN
in_IN
cell_NN
death_NN
._.

However_RB
,_,
the_DT
cellular_JJ
or_CC
molecular_JJ
factors_NNS
responsible_JJ
for_IN
a_DT
delay_NN
in_IN
B-CLL_NN
cell_NN
death_NN
are_VBP
unknown_JJ
._.

B-CLL_NN
cells_NNS
do_VBP
express_VB
receptors_NNS
for_IN
interferon-alpha_NN
-LRB-_-LRB-
IFN-alpha_NN
-RRB-_-RRB-
and_CC
IFN-gamma_NN
,_,
and_CC
activation_NN
of_IN
both_DT
has_VBZ
been_VBN
shown_VBN
to_TO
promote_VB
B-CLL_NN
survival_NN
in_FW
vitro_FW
by_IN
preventing_VBG
apoptosis_NN
._.

The_DT
interleukin-10_NN
-LRB-_-LRB-
IL-10_NN
-RRB-_-RRB-
receptor_NN
is_VBZ
another_DT
member_NN
of_IN
the_DT
IFN_NN
receptor_NN
family_NN
,_,
but_CC
its_PRP$
ligand_NN
,_,
IL-10_NN
,_,
has_VBZ
been_VBN
reported_VBN
to_TO
induce_VB
apoptosis_NN
in_IN
B-CLL_NN
cells_NNS
._.

In_IN
the_DT
current_JJ
study_NN
,_,
we_PRP
undertook_VBD
a_DT
biochemical_JJ
analysis_NN
of_IN
IL-10_NN
receptor_NN
expression_NN
on_IN
freshly_RB
isolated_VBN
B-CLL_NN
cells_NNS
and_CC
characterized_VBD
the_DT
functional_JJ
responsiveness_NN
of_IN
IL-10_NN
binding_NN
to_TO
its_PRP$
constitutively_RB
expressed_VBN
receptor_NN
._.

We_PRP
show_VBP
that_IN
B-CLL_NN
cells_NNS
bind_VBP
IL-10_NN
with_IN
significant_JJ
specificity_NN
and_CC
express_VBP
between_IN
47_CD
and_CC
127_CD
IL-10_NN
receptor_NN
sites_NNS
per_IN
cell_NN
,_,
with_IN
a_DT
dissociation_NN
constant_NN
in_IN
the_DT
range_NN
of_IN
168_CD
to_TO
426_CD
x_CC
10_CD
-LRB-_-LRB-
-12_CD
-RRB-_-RRB-
mol\/L_NN
._.

Ligand_NN
binding_NN
and_CC
activation_NN
of_IN
the_DT
IL-10_NN
receptor_NN
expressed_VBN
on_IN
B-CLL_NN
cells_NNS
results_VBZ
in_IN
the_DT
phosphorylation_NN
of_IN
signal_NN
transducer_NN
and_CC
activator_NN
of_IN
transcription_NN
1_CD
-LRB-_-LRB-
STAT1_NN
-RRB-_-RRB-
and_CC
STAT3_NN
proteins_NNS
._.

This_DT
pattern_NN
of_IN
STAT_NN
protein_NN
phosphorylation_NN
is_VBZ
identical_JJ
to_TO
IL-10_NN
receptor_NN
activation_NN
on_IN
normal_JJ
cells_NNS
and_CC
similar_JJ
to_TO
IFN-alpha_NN
-LRB-_-LRB-
STAT1_NN
and_CC
STAT3_NN
-RRB-_-RRB-
and_CC
IFN-gamma_NN
-LRB-_-LRB-
STAT1_NN
-RRB-_-RRB-
receptor_NN
activation_NN
in_IN
CLL_NN
._.

Further_RB
,_,
in_IN
consecutive_JJ
samples_NNS
of_IN
fresh_JJ
blood_NN
obtained_VBN
from_IN
patients_NNS
with_IN
B-CLL_NN
cells_NNS
,_,
the_DT
addition_NN
of_IN
IL-10_NN
inhibited_VBD
B-CLL_NN
proliferation_NN
,_,
enhanced_VBD
B-CLL_NN
differentiation_NN
,_,
but_CC
did_VBD
not_RB
induce_VB
apoptosis_NN
._.

Indeed_RB
,_,
IL-10_NN
,_,
like_IN
IFN-gamma_NN
,_,
was_VBD
able_JJ
to_TO
significantly_RB
reduce_VB
the_DT
amount_NN
of_IN
B-CLL_NN
cell_NN
death_NN
caused_VBN
by_IN
hydrocortisone-induced_JJ
apoptosis_NN
._.

We_PRP
conclude_VBP
that_IN
cytokines_NNS
,_,
which_WDT
signal_VBP
through_IN
the_DT
interferon_NN
family_NN
of_IN
receptors_NNS
,_,
have_VBP
comparable_JJ
functional_JJ
effects_NNS
on_IN
B-CLL_NN
cells_NNS
._.

